You have access to the most advanced medical therapies for multiple myeloma. Our doctors’ research has led to some of the most important drugs used to treat multiple myeloma. These include thalidomide, lenalidomide, pomalidomide, bortezomib, carfilzomib, ixazomib, elotuzumab, daratumumab, isatuximab, panobinostat, belantamab and selinexor.

John Theurer Cancer Center is one of the few sites in the world offering CAR T-cell therapy for multiple myeloma. CAR T-cell therapy requires specialized expertise. Clinical trials of CAR T-cell treatment in other blood cancers have shown that in patients whose cancer returned after prior treatment, CAR T-cell therapy helped them achieve remission that lasted for years. Learn more about CAR T-Cell therapy. 

John Theurer Cancer Center’s team has been involved in the development of advanced immunotherapy for multiple myeloma. Immunotherapy uses your body’s own immune system to find and destroy your cancer. These include CAR T-cell therapy, antibody drug conjugates and T-cell engagers, as well as checkpoint inhibitors — all of which will be mainstays of myeloma care into the future.

Some people have conditions that can turn into multiple myeloma. If you have been diagnosed with smoldering multiple myeloma or MGUS (monoclonal gammopathy of undetermined significance), we can customize a surveillance program for you.

Our doctors can monitor you and let you know if or when you may benefit from treatment. We also offer clinical trials that look at your immune system and other predictors of the best time to start treatment.

John Theurer Cancer Center has one of the largest blood and marrow stem cell programs in the country, with physicians who specialize in stem cell transplants for multiple myeloma. We perform more than 250 transplants for multiple myeloma each year, and the most transplants using donor stem cells (allogenic) for multiple myeloma than any other center in our region.

Our research focuses on reducing the complications of stem cell transplant and lowering the risk of cancer recurrence. We are the first team in the world to combine checkpoint inhibitors (drugs that work by inhibiting the proteins cancer cells use to evade detection by the immune system) after transplant. Our Blood and Marrow Stem Cell Transplant Program.